NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
47335-0083-50 | 47335-0083 | Doxorubicin Hydrochloride | Lipodox 50 | 2.0 mg/mL | Chemotherapy | Antitumor Antibiotic | Anthracycline | Intravenous | Feb 9, 2012 | May 29, 2015 | In Use |
47335-0082-50 | 47335-0082 | Doxorubicin Hydrochloride | LIPODOX | 2.0 mg/mL | Chemotherapy | Antitumor Antibiotic | Anthracycline | Intravenous | Feb 9, 2012 | May 29, 2015 | In Use |
64764-0800-28 | 64764-0800 | MARIBAVIR | Livtencity | 200.0 mg/1 | Ancillary Therapy | Miscellaneous Agent | CMV Antiviral | Oral | Nov 23, 2021 | In Use | |
64764-0800-56 | 64764-0800 | MARIBAVIR | Livtencity | 200.0 mg/1 | Ancillary Therapy | Miscellaneous Agent | CMV Antiviral | Oral | Nov 23, 2021 | In Use | |
58181-3032-05 | 58181-3032 | Lomustine | Lomustine | 100.0 mg/1 | Chemotherapy | Alkylating Agent | Nitrosourea | Oral | Sep 27, 2013 | Jan 14, 2016 | No Longer Used |
58181-3031-05 | 58181-3031 | Lomustine | Lomustine | 40.0 mg/1 | Chemotherapy | Alkylating Agent | Nitrosourea | Oral | Jul 29, 2014 | Jan 14, 2016 | No Longer Used |
58181-3030-05 | 58181-3030 | Lomustine | Lomustine | 10.0 mg/1 | Chemotherapy | Alkylating Agent | Nitrosourea | Oral | Jul 29, 2014 | Jan 14, 2016 | No Longer Used |
64842-1020-02 | 64842-1020 | Trifluridine and Tipiracil | Lonsurf | 8.19 mg/1, 20.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Oral | Nov 11, 2015 | In Use | |
64842-1020-03 | 64842-1020 | Trifluridine and Tipiracil | Lonsurf | 8.19 mg/1, 20.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Oral | Oct 21, 2015 | In Use | |
64842-1025-02 | 64842-1025 | Trifluridine and Tipiracil | Lonsurf | 6.14 mg/1, 15.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Oral | Nov 11, 2015 | In Use | |
64842-1020-01 | 64842-1020 | Trifluridine and Tipiracil | Lonsurf | 8.19 mg/1, 20.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Oral | Oct 7, 2015 | In Use | |
64842-1025-03 | 64842-1025 | Trifluridine and Tipiracil | Lonsurf | 6.14 mg/1, 15.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Oral | Oct 21, 2015 | In Use | |
64842-1025-01 | 64842-1025 | Trifluridine and Tipiracil | Lonsurf | 6.14 mg/1, 15.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Oral | Oct 7, 2015 | In Use | |
70114-0340-01 | 70114-0340 | Toripalimab-tpzi | LOQTORZI | 240.0 mg/6mL | Immunotherapy | Checkpoint Inhibitor | PD-1 | Intravenous | Oct 27, 2023 | In Use | |
83718-0000-01 | 83718-0000 | Toripalimab-tpzi | LOQTORZI | 240.0 mg/6mL | Immunotherapy | Checkpoint Inhibitor | PD-1 | Intravenous | Oct 27, 2023 | In Use | |
63539-0927-01 | 63539-0927 | Lorlatinib | Lorbrena | 25.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | ALK/ROS1 | Oral | Jan 3, 2023 | In Use | |
00069-0227-01 | 00069-0227 | Lorlatinib | Lorbrena | 25.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | ALK/ROS1 | Oral | Nov 19, 2018 | In Use | |
00069-0231-01 | 00069-0231 | Lorlatinib | Lorbrena | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | ALK/ROS1 | Oral | Nov 19, 2018 | In Use | |
70529-0053-01 | 70529-0053 | Dexamethasone Sodium Phosphate, Bupivacaine Hydrochloride | Ludaxine | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Nov 1, 2018 | In Use | |||
55513-0512-60 | 55513-0512 | Sotorasib | LUMAKRAS | 240.0 mg/1 | Chemotherapy | RAS Inhibitor | KRAS G12C | Oral | Jun 27, 2024 | In Use | |
55513-0488-24 | 55513-0488 | Sotorasib | LUMAKRAS | 120.0 mg/1 | Chemotherapy | RAS Inhibitor | KRAS G12C | Oral | May 28, 2021 | In Use | |
55513-0504-50 | 55513-0504 | Sotorasib | LUMAKRAS | 320.0 mg/1 | Chemotherapy | RAS Inhibitor | KRAS G12C | Oral | Feb 2, 2023 | In Use | |
55513-0488-02 | 55513-0488 | Sotorasib | LUMAKRAS | 120.0 mg/1 | Chemotherapy | RAS Inhibitor | KRAS G12C | Oral | May 28, 2021 | In Use | |
55513-0488-96 | 55513-0488 | Sotorasib | LUMAKRAS | 120.0 mg/1 | Chemotherapy | RAS Inhibitor | KRAS G12C | Oral | May 28, 2021 | In Use | |
00310-4700-01 | 00310-4700 | moxetumomab pasudotox | LUMOXITI | 1.0 mg/mL | Immunotherapy | Drug Antibody Conjugate | CD22 | Intravenous | Oct 24, 2018 | Sep 30, 2024 | No Longer Used |
Found 11120 results — Export these results